Risk of death and the efficacy of eritoran tetrasodium (E5564): Design considerations for clinical trials of anti-inflammatory agents in sepsis

Critical Care Medicine

Volumn 38, Issue 1, 2010, Pages 306-308

  Barochia, Amisha V ^a   Cui, Xizhong ^a   Natanson, Charles ^a   Eichacker, Peter Q ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

E5564; Eritoran tetrasodium; Inflammation; Sepsis; Treatment

Indexed keywords

CORTICOSTEROID; DROTRECOGIN; ERITORAN; PLACEBO; ANTIINFLAMMATORY AGENT; DRUG DERIVATIVE; LIPID A;

APACHE; CLINICAL TRIAL; DEATH; DRUG EFFICACY; EDITORIAL; FOOD AND DRUG ADMINISTRATION; HUMAN; MORTALITY; PHYSICIAN; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK; SEPSIS; SURVIVAL; THERAPY EFFECT; CAUSE OF DEATH; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRITICAL ILLNESS; FEMALE; INTENSIVE CARE; INTENSIVE CARE UNIT; MALE; METHODOLOGY; MULTICENTER STUDY; NOTE; PHASE 2 CLINICAL TRIAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SURVIVAL RATE;

ANTI-INFLAMMATORY AGENTS; APACHE; CAUSE OF DEATH; CRITICAL CARE; CRITICAL ILLNESS; FEMALE; HOSPITAL MORTALITY; HUMANS; INTENSIVE CARE UNITS; LIPID A; MALE; PROGNOSIS; RISK ASSESSMENT; SEPSIS; SURVIVAL RATE;

EID: 74049116462     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e3181b77fe3     Document Type: Editorial

References (19)

1. Tidswell M, Tillis W, LaRosa SP, et al: Phase 2 trial of eritoran tetrasodium (E5564), a Toll-like receptor 4 antagonist, in patients with severe sepsis. Crit Care Med 2010; 38: 72-83
2. Eichacker PQ, Parent C, Kalil A, et al: Risk and the efficacy of antiinflammatory agents: Retrospective and confirmatory studies of sepsis. Am J Respir Crit Care Med 2002; 166:1197-1205
3. Cui X, Parent C, Macarthur H, et al: Severity of sepsis alters the effects of superoxide anion inhibition in a rat sepsis model. J Appl Physiol 2004; 97:1349-1357
4. Bernard GR, Vincent JL, Laterre PF, et al: Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344:699-709
5. Deans KJ, Minneci PC, Eichacker PQ, et al: The efficacy of drotrecogin alfa depends on severity of illness. Crit Care Med 2004; 32:2347
6. Warren HS, Suffredini AF, Eichacker PQ, et al: Risks and benefits of activated protein C treatment for severe sepsis. N Engl J Med 2002; 347:1027-1030
7. Minneci PC, Deans KJ, Eichacker PQ, et al: The effects of steroids during sepsis depend on dose and severity of illness: An updated meta-analysis. Clin Microbiol Infect 2009; 15:308-318
8. Annane D, Bellissant E, Bollaert PE, et al: Corticosteroids in the treatment of severe sepsis and septic shock in adults: A systematic review. JAMA 2009; 301:2362-2375
9. Mullarkey M, Rose JR, Bristol J, et al: Inhibition of endotoxin response by E5564, a novel Toll-like receptor 4-directed endotoxin antagonist. J Pharmacol Exp Ther 2003; 304: 1093-1102
10. Rossignol DP, Lynn M: TLR4 antagonists for endotoxemia and beyond. Curr Opin Investig Drugs 2005; 6:496-502
11. Abraham E, Laterre PF, Garg R, et al: Dro-trecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med 2005; 353:1332-1341
12. Efficacy and safety of drotrecogin alfa (activated) in adult patients with septic shock; NCT00604214. Available at: http://clinicaltrials. gov/ct2/show/NCT00604214?term=activated-protein+c&rank=19. Accessed June 26, 2009
13. Ridley S, Lwin A, Wyncoll D, et al: Drotrecogin alfa (activated): Diffusion from clinical trials to clinical practice. Eur J Anaesthesiol 2008; 25:211-216
14. Rowan KM, Welch CA, North E, et al: Drotrecogin alfa (activated): Real-life use and outcomes for the UK. Crit Care 2008; 12:R58
15. Cerra FB, Negro F, Abrams J: APACHE II score does not predict multiple organ failure or mortality in postoperative surgical patients. Arch Surg 1990; 125:519-522
16. Goldhill DR, Withington PS: The effect of casemix adjustment on mortality as predicted by APACHE II. Intensive Care Med 1996; 22:415-419
17. Rutledge R, Fakhry SM, Rutherford EJ, et al: Acute Physiology and Chronic Health Evaluation (APACHE II) score and outcome in the surgical intensive care unit An analysis of multiple intervention and outcome variables in 1,238 patients. Crit Care Med 1991; 19:1048-1053
18. Dragsted L, Jorgensen J, Jensen NH, et al: Interhospital comparisons of patient outcome from intensive care: Importance of lead-time bias. Crit Care Med 1989; 17:418-422
19. Fery-Lemonnier E, Landais P, Loirat P, et al: Evaluation of severity scoring systems in ICUs\-Translation, conversion and definition ambiguities as a source of inter-observer variability in APACHE II, SAPS and OSF. Intensive Care Med 1995; 21:356-360